Solomon. DELIVER Design Manuscript
Details of the DELIVER study design and statistical analysis
Solomon. DELIVER primary Manuscript
DELIVER primary results manuscript
Vaduganathan. SGLT2 Meta-analysis
Meta-analysis of DELIVER, EMPEROR-Preserved and other SGLT2 trials
Myhre. NT-proBNP in DELIVER
Influence of NT-proBNP on outcomes in DELIVER
Butt. Atrial fibrillation in DELIVER
Influence of atrial fibrillation on outcomes and effectiveness of dapagliflozin in DELIVER
Peikert. Age and Effectiveness and Safety of Dapagliflozin in DELIVER
Influence of Age on the safety and effectiveness of dapagliflozin in DELIVER
Desai. DELIVER DAPA-HF Cause of Death
Mode of death across the spectrum in ejection fraction in DAPA-HF and DELIVER
Lam. Solomon. On my mind...
Discussion of why the results of DELIVER suggest that SGLT2 inhibitors behave differently from other therapies in Heart Failure
McCausland. Renal Outcomes in DELIVER
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fractio
Inzucchi. DELIVER Diabetes and Pre-Diabetes
Effect of Dapagliflozin on Patients with Diabetes or Pre-Diabetes and Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Vardeny. Dapagliflozin in Heart Failure with Improved Ejection Fraction
Effect of Dapagliflozin in patients with heart failure with improved ejection fraction
Yang. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
Butt. Dapagliflozin and Gout
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout
A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER
Kondo. Jering. DELIVER HF Duration
Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial
Peikert. DELIVER KCCQ Components
Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial
Bhatt. Dapagliflozin KCCQ across LVEF
Effect of Dapagliflozin on Health Status and Quality-of-Life Across the Spectrum of Ejection Fraction: Participant-Level Pooled Analysis from the DAPA-HF & DELIVER Trials
Peikert. DELIVER according to Polypharmacy status
Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status
Chatur. DELIVER Diuretics
Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Ostrominski. Overlapping Cardio-Renal-Metabolic conditions in DELIVER.
Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Kondo. Dapagliflozin effectiveness according to geographic location.
Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure
Pabon. Influence of background therapy on efficacy of Dapagliflozin.
Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial
Butt. DELIVER COPD
Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in HFmrEF/HFpEF: Insights from DELIVER
Peikert. DELIVER Trial: Use and Implications of Beta-Blockers
Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial
Ostrominski. DELIVER Treatment-Resistant Hypertension
Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial
Mc Causland. DELIVER and eGFR Decline in HFmrEF/HFpEF
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial
Vardeny. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction
Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial
Bhatt. Dapagliflozin Cost Effectiveness
Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials
Solomon. DELIVER Baseline Manuscript
Detailed baseline characteristics of DELIVE
Jhund. DAPA-HF DELIVER pooled
Prespecified pooled analysis of DELIVER and DAPA-HF
Cunningham. Dapagliflozin in hospitalized or recently hospitalized patients
Effect of dapagliflozin in hospitalized or recently hospitalized patients with mildly reduced or preserved ejection fraction
Adamson. BMI and Dapagliflozin in DELIVER
Influence of BMI on effectiveness of dapagliflozin in DELIVER
Butt. Frailty in DELIVER
Effect of frailty on effectiveness and safety of dapagliflozin in DELIVER
Ostrominski. NYHA in DELIVER
NYHA Class and effectiveness of Dapagliflozin and effect of dapagliflozin on NYHA class in DELIVER
Vaduganathan. Time to Clinical Benefit
Time to clinical benefit in DELIVER
Selvaraj. BP in DELIVER
Effect of blood pressure on efficacy of dapagliflozin and influence of dapagliflozin on blood pressure in DELIVER
Vaduganathan. Claggett. Lifetime Benefit in DELIVER
Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure
Wang. Sex Differences in DAPA-HF and DELIVER
Effect of Dapagliflozin according to sex across the EF spectrum
Kosiborod. Effect of Dapagliflozin on Health Status and Quality of Life
Effect of Dapagliflozin on Health Status and Quality of Life in Mildly Reduced or Preserved Ejection Fraction
Talha. Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US
Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US
Butt. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
Vaduganathan. All-Cause Hospitalizations
Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction
Jhund. Claggett. DELIVER Recurrent Events
Effect of Dapagliflozin on Total Heart Failure Events in Patients
With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Chatur. Kondo. Dapagliflozin HF Hospitalization Complexity
Effects of Dapagliflozin on Heart Failure Hospitalizations According to Severity of Inpatient Course: Insights from DELIVER and DAPA-HF
Chatur. DELIVER Subacute Renal and Hemodynamics
Renal and Blood Pressure Effects of Dapagliflozin in Recently Hospitalized Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from the DELIVER Trial
Butt. Dapagliflozin effectiveness in patients with HF and PAD
Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER
Bhatt. DELIVER Operation challenges during COVID-19.
Operational challenges and mitigation measures during the COVID-19 pandemic-Lessons from DELIVER
Booth. DELIVER. Cost-Effectiveness in Europe
The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: a European health-economic analysis of the DELIVER trial
Chatur. Dapagliflozin in patients with Kidney Function eGFR Below 25
Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
Chatur. Vaduganathan. DELIVER Outpatient Worsening.
Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial
Chatur. Vaduganathan. Dapagliflozin & Deterioration in Renal Function
Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
Bhatt. DELIVER Trial & Impact of COVID-19 in Enrolled Population
Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial
Kondo. Butt. Dapagliflozin Efficacy of According to Heart Rate
Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER
Butt. Dapagliflozin & Sleep Apnea
Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level
Pooled Meta-Analysis of DAPA-HF and DELIVER
Wang. DELIVER Patients in Asia
Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial
Peikert. Dapagliflozin in Patients with HF & previous MI
Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER
